Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4

Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease

Authors Kimmel SR

Published 8 August 2008 Volume 2008:4(4) Pages 739—745


Sanford R Kimmel

University of Toledo College of Medicine, Department of Family Medicine, Toledo, OH, USA

Abstract: Invasive meningococcal disease occurs worldwide causing an estimated 50,000–135,000 deaths each year in addition to significant sequelae. In developed countries the disease is usually sporadic but outbreaks and epidemics, usually due to serogroups B and C, have occurred. In the US, an increasing number of cases are due to serogroup Y. In developing nations, epidemics due to serogroups A and more recently W-135, are common. The tetravalent meningococcal conjugate vaccine to serogroups A, C, Y, and W-135 (MCV4) has been demonstrated to be highly immunogenic and promote immune memory. This article will describe the rationale for the vaccine and its potential role to significantly decrease mortality and morbidity of meningococcal disease in those areas and populations at greatest risk from these serogroups.

Keywords: meningococcal disease, tetravalent meningococcal conjugate vaccine, serogroup

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]